Your Directors have great pleasure in presenting their Annual Report together with the Audited Financial Statements ot the Company for the financial year ended 31st March, 2025.

1. Financial Highlights and Strength

1.1. During the year under review, the Company has maintained its stature as a Zero-Debt Company, standing strong on a foundation of prudent fiscal discipline and resource optimization.

1.2. The Company’s Reserves and Surplus have crossed ?3 Crores, reflecting consistent conservation of financial resources and a strong capacity to fund expansion and growth.

1.3. This resilient financial position provides a safeguard against market volatility and supports the Company's aspirations of sustaining and expanding its operations in diversified business segments.

2. Performance and Operations

2.1. The financial year witnessed significant challenges arising from the onslaught of Artificial Intelligence (Al) products and services disrupting traditional business models. Nevertheless, the Company has shown sustained business continuity by adapting to this evolving environment.

2.2. One of the hallmarks of the Company's operational strategy has been the preservation of cordial and long-term client relationships, which has ensured recurring business and goodwill.

2.3. The Company continues to focus on balancing traditional revenue streams with innovative explorations into new technology-enabled service areas.

3. Major Developments During the Year

3.1. Exploration of New Business Opportunities - The Company has actively engaged in evaluating emerging opportunities across technology-driven verticals.

3.2. Expansion of Network Reach - Strengthening alliances and expanding operational presence across broader geographies and platforms.

3.3. Sustaining E-Commerce in Healthcare - The Company is proud to have become one of the first in the industry to establish itself as a healthcare packaged product provider for the SME segment. Today, the Company sustains an active e-commerce portfolio of more than 75 products, downloadable solutions, online services, and maintenance offerings. This initiative represents not only a diversification of revenue streams but also a pioneering achievement in making healthcare technology accessible and affordable for small and medium enterprises.

4. Outlook for the Coming Year

4.1. The foremost strategic priority is the revocation of the temporary suspension in trading by BSE.

4.2. Your Company has already taken corrective measures to ensure timely submission of quarterly and annual results in the revised SEBI formats, thereby aligning fully with evolving compliance standards.

4.3. The future focus remains on consolidating current strengths, leveraging Al advancements, and sustaining the momentum of healthcare e-commerce operations, ensuring scalability, product innovation, and customer retention.

5. Corporate Governance and Compliance

5.1. The Board reaffirms its commitment to the highest standards of transparency, accountability, and integrity in governance.

5.2. The Company has meticulously complied with requirements under the Companies Act, 2013, the rules made thereunder, SEBI (LODR) Regulations, and guidelines issued by BSE.

5.3. Constructive cooperation with BSE listing and compliance teams has ensured the timely rectification of disclosures and filings, thereby reinforcing the Company’s compliance culture.

5.4. The Board also recognizes the valuable oversight of statutory auditors and regulators, which has strengthened internal controls and enhanced governance practices.

6. Secretarial Audit

6.1. Pursuant to the provisions of Section 204 of the Companies Act, 2013, and the Rules made thereunder, the Company has appointed a qualified Practicing Company Secretary to conduct the Secretarial Audit of the Company.

6.2. The Secretarial Audit Report for the financial year ended 31st March, 2025, is submitted in Exchange and available publicly.

6.3. There has been no adverse observations in the Secretarial Audit Report, however the Board, and necessary corrective have noted the suggestions if any, measures are being undertaken to ensure continuous improvement in compliance practices.

7. Acknowledgements

Your Directors wish to place on record their sincere appreciation to:

7.1. The Board of Directors - for their wisdom, guidance, and stewardship in navigating the Company through a transformative year.

7.2. Auditors - for their valuable insights, independent opinion, and contribution to financial transparency.

7.3. Employees - for their dedication, innovation, and resilience, which form the bedrock of the Company's progress.

7.4. Registrars, Depositories, and Statutory Bodies - for their professional support and cooperation.

7.5. GST and Regulatory Authorities - for their constructive engagement and timely guidance.

7.6. BSE Compliance and Listing Teams - for their constant support, corrections, and guidance in enabling the Company to align with changing SEBI reporting formats.

7.7. Shareholders, Stakeholders, and Clients - whose trust, confidence, and long-term partnerships remain the most valuable assets of the Company.

8. Conclusion

8.1. The Board remains confident that Netripples Software Limited is well-positioned to achieve sustainable growth by blending financial conservatism with innovative foresight

8.2. With the strong reserve base, debt-free status, and its pioneering position in healthcare e-commerce packaged products for SMEs, the Company is poised to create enduring stakeholder value.

8.3. Your Directors reiterate their commitment to continuing the journey with humility, responsibility, and determination to deliver excellence.